Two targeted drugs for malignant peripheral nerve sheath tumor
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests two oral targeted drugs, avutometinib and defactinib, for malignant peripheral nerve sheath tumor (MPNST) that has come back or spread. The hope is that these drugs can shrink or slow the tumor where chemotherapy hasn't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years or older and have a body surface area (a measure of your size) of at least 1.5 square meters.
- You have been diagnosed with a type of tumor called malignant peripheral nerve sheath tumor (MPNST) that has come back, spread, or cannot be removed with surgery.
- You have a tissue sample (biopsy) from your tumor that can be used for research.
- Your tumor can be measured on scans (like CT or MRI).
- You must have had at least one round of chemotherapy that didn't work, or you chose not to have chemotherapy.
- You have not previously been treated with a combination of a MEK and FAK inhibitor together, and you have not had severe side effects from a MEK or FAK inhibitor alone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
This trial tests two targeted drugs, mirdametinib and vorinostat, to see if they can shrink MPNST tumors in people with NF1 before surgery. It is for patients whose tumors lack a specific protein marker (H3K27me3).
This trial tests a combination of two investigational drugs for people with NF2-related tumors. The drugs target specific pathways to help shrink or slow growth of vestibular schwannomas and meningiomas.
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial tests a new combination of two targeted therapy drugs (avutometinib and defactinib) plus standard chemotherapy (mFOLFIRINOX) given before any other treatment for pancreatic cancer. The goal is to see if this combination can shrink tumors more effectively and improve outcomes for patients with advanced pancreatic cancer.
Hear when a new MPNST (Malignant Peripheral Nerve Sheath Tumor) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.